



SVB Securities Serves as Exclusive Financial Advisor to Asceneuron on its Licensing Agreement with Ferrer for ASN90 for the Treatment of Progressive Supranuclear Palsy (PSP)

Key Transaction Highlights

- On February 22, 2023, Asceneuron SA ("Asceneuron") and Ferrer International SA ("Ferrer") announced the signing of a licensing agreement in which Ferrer obtains the exclusive worldwide rights to develop and commercialize ASN90 for progressive supranuclear palsy (PSP), an orphan, neurodegenerative disease with a high unmet medical need.
- Ferrer will now conduct a Phase II clinical study to determine the efficacy and optimal dose range of ASN90.
- Asceneuron will receive an upfront fee and multiple development, regulatory and commercial milestones payments. Asceneuron is also eligible to receive future double-digit royalties on worldwide net sales of ASN90.
- SVB Securities acted as exclusive financial adviser to Asceneuron.

About Asceneuron

Asceneuron is a clinical stage biotech company focused on the development of orally administrable therapies for debilitating neurodegenerative disorders with high unmet medical need. The pipeline reflects their ambition to develop treatments for a wide range of neurodegenerative diseases, including orphan neuropathies, Alzheimer's and Parkinson's disease. Asceneuron has two clinical stage small molecule (2-*deoxy*-2-*fluoro*-adenosine) inhibitors in development for the treatment of neuropathies including one that is in phase I studies for Parkinson's disease, one that is in phase I studies for Alzheimer's disease and related disorders.

About Ferrer

Ferrer is a privately held biopharmaceutical company dedicated to making a positive impact in society. Founded in Barcelona in 1959, the company is currently present in more than a hundred countries and has a team of over 1,000 people. Ferrer's experience and knowledge make a difference in the treatment of primary hypertension, the nervous system, pain, cardiovascular, gastroenterology and dermatology. In these areas, Ferrer offers trusted products that meet the highest European quality standards. It manufactures many of these products itself.

For more information visit the Asceneuron [Web Site](#). For more information visit the SVB Securities website [Web Site](#).

This press release contains forward-looking statements and is not to be construed as a recommendation or offer of securities by SVB Securities LLC. The information contained herein is not to be construed as a recommendation or offer of securities by SVB Securities LLC. This press release is not to be construed as a recommendation or offer of securities by SVB Securities LLC. This press release is not to be construed as a recommendation or offer of securities by SVB Securities LLC.

SVB SECURITIES
100 West Street
10th Floor
New York, NY 10038

CHICAGO OFFICE
100 West Street
10th Floor
Chicago, IL 60601

SEATTLE OFFICE
100 West Street
10th Floor
Seattle, WA 98101

NEW YORK OFFICE
100 West Street
10th Floor
New York, NY 10038

NEW YORK OFFICE
100 West Street
10th Floor
New York, NY 10038

An SVB Company
info@svbsec.com